Search

Your search keyword '"Lung cancer, Non-small cell -- Care and treatment -- Genetic aspects"' showing total 215 results
Start Over Descriptor "Lung cancer, Non-small cell -- Care and treatment -- Genetic aspects"
215 results on '"Lung cancer, Non-small cell -- Care and treatment -- Genetic aspects"'

1. Effect of cryoablation on the spatial transcriptomic landscape of the immune microenvironment in non-small cell lung cancer

Author

Zhou, Jun, Wang, Shengxi, Liu, Ming, and Li, Zhaopei

Subjects
Care and treatment, Usage, Physiological aspects, Genetic aspects, Health aspects, Cryotherapy -- Usage -- Physiological aspects -- Genetic aspects, Transcription (Genetics) -- Health aspects -- Physiological aspects, Immune system -- Health aspects -- Genetic aspects, Non-small cell lung cancer -- Care and treatment -- Genetic aspects, Cold -- Health aspects, Lung cancer, Non-small cell -- Care and treatment -- Genetic aspects, Genetic transcription -- Health aspects -- Physiological aspects
Abstract

Author(s): Jun Zhou [1]; Shengxi Wang [1]; Ming Liu [2]; Zhaopei Li (corresponding author) [1] INTRODUCTION Immune checkpoint inhibitors are one of the standard treatment options for non-small-cell lung cancer [...], Background: Cryoablation induces antitumor immune responses. Spatial transcriptomic landscape technology has been used to determine the micron-level panoramic transcriptomics of tissue slices in situ. Methods: The effects of cryoablation on the immune microenvironment in non-small cell lung cancer (NSCLC) were explored by comparing the Whole Transcriptome Atlas (WTA) panel of immune cells before and after cryoablation using the spatial transcriptomic landscape. Results: The bioinformatics analysis showed that cryoablation significantly affected the WTA of immune cells, particularly genes related to cellular components, biological processes, molecular functions, proliferation and migration, and cytokine-cytokine receptor interaction signaling pathways. Conclusions: The findings of this study suggest that cryoablation significantly impacts the biological functions of immune cells in the tumor microenvironment of NSCLC through multiple mechanisms. Keywords: Cryoablation, immune microenvironment, non-small cell lung cancer, spatial transcriptomic landscape

Published
2024
Full Text
View/download PDF

2. Investigators from University of Toronto Zero in on Non-Small Cell Lung Cancer (Predictive [18f]-fdg Pet/ct-based Radiogenomics Modelling of Driver Gene Mutations In Non-small Cell Lung Cancer)

Subjects
University of Toronto, Care and treatment, Models, Genetic aspects, Positron emission tomography -- Models, Physical fitness -- Models, Cancer genetics -- Care and treatment -- Genetic aspects, Genes -- Genetic aspects -- Models, Gene mutation -- Models -- Genetic aspects, Medical research -- Models, Small cell lung cancer -- Genetic aspects -- Care and treatment, Non-small cell lung cancer -- Care and treatment -- Genetic aspects, Gene mutations -- Models -- Genetic aspects, Medicine, Experimental -- Models, PET imaging -- Models, Lung cancer, Small cell -- Genetic aspects -- Care and treatment, Cancer -- Genetic aspects, Lung cancer, Non-small cell -- Care and treatment -- Genetic aspects
Abstract

2025 JAN 4 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- A new study on Oncology - Non-Small Cell Lung Cancer is now [...]

Published
2025

3. China NMPA accepts and grants priority review status to Hutchmed's NDA for Orpathys & Tagrisso combination in lung cancer patients with MET amplification after progression on first-line EGFR inhibitor therapy

Subjects
AstraZeneca PLC -- Foreign operations, Tagrisso (Medication), Care and treatment, Genetic aspects, Foreign operations, Osimertinib, Epidermal growth factors -- Genetic aspects, Pemetrexed, Cancer patients -- Care and treatment, Non-small cell lung cancer -- Care and treatment -- Genetic aspects, Cancer metastasis -- Genetic aspects -- Care and treatment, Metastasis -- Genetic aspects -- Care and treatment, Lung cancer, Non-small cell -- Care and treatment -- Genetic aspects, Epidermal growth factor -- Genetic aspects
Abstract

Hutchmed (China) Limited, an innovative, commercial-stage, biopharmaceutical company, announces that the New Drug Application (NDA) for the combination of Orpathys (savolitinib) and Tagrisso (osimertinib) for the treatment of patients with [...]

Published
2025

4. FDA Grants Breakthrough Therapy Designation to Sacituzumab Tirumotecan (sac-TMT) for Treatment of Certain Patients sith Previously Treated Advanced or Metastatic NSCLC with EGFR Mutations

Subjects
United States. Food and Drug Administration, Merck Research Laboratories, Metastasis -- Genetic aspects -- Care and treatment, Biological products -- Genetic aspects, Pemetrexed, Lung cancer, Non-small cell -- Care and treatment -- Genetic aspects, Chemotherapy, Cancer -- Chemotherapy, Epidermal growth factor -- Genetic aspects, Arts and entertainment industries
Abstract

Merck, known as MSD outside of the United States and Canada, reported that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to sacituzumab tirumotecan (sac-TMT) for [...]

Published
2024

5. FDA Grants Breakthrough Therapy Designation to Sacituzumab Tirumotecan (sac-TMT) for Treatment of Certain Patients sith Previously Treated Advanced or Metastatic NSCLC with EGFR Mutations

Subjects
United States. Food and Drug Administration, Merck Research Laboratories, Metastasis -- Genetic aspects -- Care and treatment, Biological products -- Genetic aspects, Pemetrexed, Lung cancer, Non-small cell -- Care and treatment -- Genetic aspects, Chemotherapy, Cancer -- Chemotherapy, Epidermal growth factor -- Genetic aspects, Arts and entertainment industries
Abstract

Merck, known as MSD outside of the United States and Canada, reported that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to sacituzumab tirumotecan (sac-TMT) for [...]

Published
2024

6. US FDA grants breakthrough therapy designation to sacituzumab tirumotecan to treat certain patients with previously treated advanced or metastatic nonsquamous NSCLC with EGFR mutations

Subjects
Merck Research Laboratories, United States. Food and Drug Administration, Keytruda (Medication), Care and treatment, Genetic aspects, Chemotherapy, Pembrolizumab, Epidermal growth factors -- Genetic aspects, Pemetrexed, Non-small cell lung cancer -- Care and treatment -- Genetic aspects, Cancer metastasis -- Genetic aspects -- Care and treatment, Biological products -- Genetic aspects, Metastasis -- Genetic aspects -- Care and treatment, Lung cancer, Non-small cell -- Care and treatment -- Genetic aspects, Cancer -- Chemotherapy, Epidermal growth factor -- Genetic aspects
Abstract

Merck, known as MSD outside of the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to sacituzumab tirumotecan (sac-TMT) for [...]

Published
2024

7. FDA Grants Breakthrough Therapy Designation to Sacituzumab Tirumotecan (sac-TMT) for Treatment of Certain Patients sith Previously Treated Advanced or Metastatic NSCLC with EGFR Mutations

Subjects
United States. Food and Drug Administration, Merck Research Laboratories, Metastasis -- Genetic aspects -- Care and treatment, Biological products -- Genetic aspects, Pemetrexed, Lung cancer, Non-small cell -- Care and treatment -- Genetic aspects, Chemotherapy, Cancer -- Chemotherapy, Epidermal growth factor -- Genetic aspects, Arts and entertainment industries
Abstract

Merck, known as MSD outside of the United States and Canada, reported that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to sacituzumab tirumotecan (sac-TMT) for [...]

Published
2024

8. European Union recommends approval of AstraZeneca's Tagrisso for patients with unresectable EGFR-mutated lung cancer

Subjects
AstraZeneca PLC, European Union, Tagrisso (Medication), Care and treatment, Genetic aspects, Durvalumab, Clinical trials, Osimertinib, Epidermal growth factors -- Genetic aspects, Pharmaceutical industry, Non-small cell lung cancer -- Care and treatment -- Genetic aspects, Lung cancer, Non-small cell -- Care and treatment -- Genetic aspects, Epidermal growth factor -- Genetic aspects
Abstract

AstraZeneca's Tagrisso (osimertinib) has been recommended for approval in the European Union (EU) for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC) whose tumours [...]

Published
2024

9. Pierre Fabre Laboratories receives European Commission Approval for BRAFTOVI®encorafenib in combination with MEKTOVI® binimetinib for the treatment of adult patients with advanced non-small cell lung cancer NSCLC with a BRAFV600E mutation

Subjects
European Union. European Commission, Braftovi (Medication), Mektovi (Medication), Care and treatment, Genetic aspects, Clinical trials, Encorafenib, Physical fitness, Binimetinib, Small cell lung cancer -- Genetic aspects -- Care and treatment, Drug approval, Non-small cell lung cancer -- Care and treatment -- Genetic aspects, Lung cancer, Small cell -- Genetic aspects -- Care and treatment, Lung cancer, Non-small cell -- Care and treatment -- Genetic aspects
Abstract

2024 SEP 14 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Pierre Fabre Laboratories announced that the European Commission (EC) has approved BRAFTOVI [...]

Published
2024

10. Data from Qujing Update Knowledge in Squamous Cell Carcinoma (Afatinib as first-line treatment for advanced lung squamous cell carcinoma harboring uncommon EGFR G719C and S768I co-mutation: A case report and literature review)

Subjects
Care and treatment, Genetic aspects, Physical fitness, Afatinib, Squamous cell carcinoma -- Genetic aspects -- Care and treatment, Epidermal growth factors -- Genetic aspects, Drug approval, Non-small cell lung cancer -- Care and treatment -- Genetic aspects, Lung cancer, Non-small cell -- Care and treatment -- Genetic aspects, Epidermal growth factor -- Genetic aspects
Abstract

2024 AUG 17 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators discuss new findings in squamous cell carcinoma. According to news reporting [...]

Published
2024

11. Findings from First Affiliated Hospital of Guangzhou Medical University Advance Knowledge in Tyrosine Kinase Inhibitors (EGFR-TKI as neoadjuvant treatment in patients with NSCLC with EGFR sensitive mutation: A retrospective real-world analysis)

Subjects
Care and treatment, Analysis, Genetic aspects, Reports, Physical fitness -- Analysis -- Reports, Tyrosine -- Analysis -- Reports -- Genetic aspects, Epidermal growth factors -- Reports -- Genetic aspects -- Analysis, Phenols (Class of compounds) -- Reports -- Analysis, Non-small cell lung cancer -- Care and treatment -- Genetic aspects, Phenols -- Reports -- Analysis, Lung cancer, Non-small cell -- Care and treatment -- Genetic aspects, Epidermal growth factor -- Reports -- Genetic aspects -- Analysis
Abstract

2024 JUL 20 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- New study results on tyrosine kinase inhibitors have been published. According to [...]

Published
2024

12. Researchers from University of Colorado Anschutz Medical Campus Detail New Studies and Findings in the Area of Non-Small Cell Lung Cancer (The Role of Local Therapy for Oligo-Progressive Disease in Oncogene-Addicted Non-Small-Cell Lung Cancer)

Subjects
University of Colorado -- Reports, Care and treatment, Analysis, Genetic aspects, Reports, Physical fitness -- Analysis -- Reports, Diseases -- Genetic aspects -- Care and treatment -- Colorado, Cancer genetics -- Care and treatment -- Genetic aspects, Cancer research -- Reports -- Analysis -- Genetic aspects, Small cell lung cancer -- Genetic aspects -- Care and treatment, Radiotherapy -- Analysis -- Reports, Non-small cell lung cancer -- Care and treatment -- Genetic aspects, Oncology, Experimental -- Reports -- Analysis -- Genetic aspects, Lung cancer, Small cell -- Genetic aspects -- Care and treatment, Cancer -- Genetic aspects -- Research, Lung cancer, Non-small cell -- Care and treatment -- Genetic aspects
Abstract

2024 JUL 13 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- New study results on non-small cell lung cancer have been published. According [...]

Published
2024

13. Data from Zhejiang Cancer Hospital Provide New Insights into Lung Cancer (Changing ALK-TKI mechanisms of resistance in re-biopsies of ALK-rearranged NSCLC: ALK mutations followed by SCLC-like histologic transformation: A case report)

Subjects
Care and treatment, Genetic aspects, Physical fitness, Crizotinib, Ceritinib, Lorlatinib, Drug resistance -- Care and treatment -- Genetic aspects, Lymphomas -- Genetic aspects -- Care and treatment, Non-small cell lung cancer -- Care and treatment -- Genetic aspects, Alectinib, Lung cancer, Non-small cell -- Care and treatment -- Genetic aspects
Abstract

2024 JUN 29 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Fresh data on lung cancer are presented in a new report. According [...]

Published
2024

14. Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy

Subjects
Taiho Pharmaceutical Company Ltd. -- Product development, Care and treatment, Genetic aspects, Product development, Clinical trials, Small cell lung cancer -- Genetic aspects -- Care and treatment, Epidermal growth factors -- Genetic aspects, Non-small cell lung cancer -- Care and treatment -- Genetic aspects, Lung cancer, Small cell -- Genetic aspects -- Care and treatment, Lung cancer, Non-small cell -- Care and treatment -- Genetic aspects, Epidermal growth factor -- Genetic aspects
Abstract

TOKYO, PRINCETON, N.J. and CAMBRIDGE, Mass., Jan. 28, 2025 /PRNewswire/ -- Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc., and Cullinan Therapeutics, Inc., announced today the https://c212.net/c/link/?t=0&l=en&o=4350306-1&h=2167446581&u=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04036682%3Fterm%3DNCT04036682&a=REZILIENT1+trial, a Phase 1/2 clinical [...]

Published
2025

15. Tagrisso approved in EU based on LAURA trial

Subjects
AstraZeneca PLC -- Product development, Lung cancer, Non-small cell -- Care and treatment -- Genetic aspects, Drug approval, Epidermal growth factor -- Genetic aspects, Business, international, European Union
Abstract

Helsinki: AstraZeneca PLC has issued the following news release: AstraZeneca's Tagrisso (osimertinib) has been approved in the European Union (EU) for the treatment of adult patients with locally advanced, unresectable [...]

Published
2024

16. FDA Grants Breakthrough Therapy Designation to Sacituzumab Tirumotecan (sac-TMT) for the Treatment of Certain Patients With Previously Treated Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer With EGFR Mutations

Subjects
United States. Food and Drug Administration, Merck & Company Inc., Metastasis -- Genetic aspects -- Care and treatment, Biological products -- Genetic aspects, Viral antibodies -- Genetic aspects, Lung cancer, Small cell -- Genetic aspects -- Care and treatment, Antigens -- Genetic aspects, Pemetrexed, Lung cancer, Non-small cell -- Care and treatment -- Genetic aspects, Chemotherapy, Cancer -- Chemotherapy, Antibodies -- Genetic aspects, Epidermal growth factor -- Genetic aspects, Business, Business, international, Keytruda (Medication)
Abstract

First breakthrough therapy designation for investigational sac-TMT in the U.S. RAHWAY, N.J. -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the [...]

Published
2024

17. Department of Oncology Researchers Have Provided New Study Findings on Kinase Inhibitors (Activity of afatinib in patients with NSCLC harboring novel uncommon EGFR mutations with or without co-mutations: a case report)

Subjects
Care and treatment, Genetic aspects, Physical fitness, Afatinib, Epidermal growth factors -- Genetic aspects, Non-small cell lung cancer -- Care and treatment -- Genetic aspects, Lung cancer, Non-small cell -- Care and treatment -- Genetic aspects, Epidermal growth factor -- Genetic aspects
Abstract

2024 MAY 25 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Research findings on kinase inhibitors are discussed in a new report. According [...]

Published
2024

18. Southeast University Researchers Release New Data on Kinase Inhibitors (Successful treatment of a patient with NSCLC carrying uncommon compound L861Q/G719X epidermal growth factor receptor mutations using Afatinib)

Subjects
Care and treatment, Genetic aspects, Physical fitness, Afatinib, Epidermal growth factors -- Genetic aspects, Cancer patients -- Care and treatment, Non-small cell lung cancer -- Care and treatment -- Genetic aspects, Lung cancer, Non-small cell -- Care and treatment -- Genetic aspects, Epidermal growth factor -- Genetic aspects
Abstract

2024 APR 20 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on kinase inhibitors have been published. According to news [...]

Published
2024

19. Merck starts phase 3 trial of MK-1084 in combo with Keytruda for first-line treatment of certain patients with metastatic NSCLC

Subjects
Merck Research Laboratories -- Product development, Keytruda (Medication) -- Product development, Care and treatment, Genetic aspects, Product development, Clinical trials, Pharmaceutical industry -- Product development, Cancer metastasis -- Genetic aspects -- Care and treatment, Non-small cell lung cancer -- Care and treatment -- Genetic aspects, Metastasis -- Genetic aspects -- Care and treatment, Lung cancer, Non-small cell -- Care and treatment -- Genetic aspects
Abstract

Merck, known as MSD outside of the United States and Canada, announced it has initiated a phase 3 clinical trial evaluating MK-1084, an investigational oral selective KRAS G12C inhibitor, in [...]

Published
2024

20. New Non-Small Cell Lung Cancer Study Findings Recently Were Reported by Researchers at All India Institute of Medical Sciences (AIIMS) [Epidermal Growth Factor Receptor (Egfr) Mutations In the Serum of Non-small Cell Lung Cancer (Nsclc) Patients ...]

Subjects
Care and treatment, Genetic aspects, Cancer research -- Genetic aspects, Biochemistry -- Genetic aspects, Small cell lung cancer -- Genetic aspects -- Care and treatment, Epidermal growth factors -- Genetic aspects, Non-small cell lung cancer -- Care and treatment -- Genetic aspects, Oncology, Experimental -- Genetic aspects, Lung cancer, Small cell -- Genetic aspects -- Care and treatment, Lung cancer, Non-small cell -- Care and treatment -- Genetic aspects, Cancer -- Research, Epidermal growth factor -- Genetic aspects
Abstract

2025 FEB 7 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Data detailed on Oncology - Non-Small Cell Lung Cancer have been presented. According [...]

Published
2025

21. Studies from Chongqing in the Area of Non-Small Cell Lung Cancer Described (Diagnostic accuracy of MRI-based radiomic features for EGFR mutation status in non-small cell lung cancer patients with brain metastases: a meta-analysis)

Subjects
Oncology, Experimental -- Reports -- Genetic aspects, Metastasis -- Genetic aspects -- Care and treatment, Lung cancer, Small cell -- Genetic aspects -- Care and treatment, Magnetic resonance imaging -- Reports, Lung cancer, Non-small cell -- Care and treatment -- Genetic aspects, Cancer -- Research, Epidermal growth factor -- Reports -- Genetic aspects, Health
Abstract

2025 JAN 24 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- New study results on non-small cell lung cancer have been published. According to [...]

Published
2025

22. FDA Grants Breakthrough Therapy Designation to Sacituzumab Tirumotecan (sac-TMT) for Treatment of Certain Patients sith Previously Treated Advanced or Metastatic NSCLC with EGFR Mutations

Subjects
United States. Food and Drug Administration, Merck Research Laboratories, Metastasis -- Genetic aspects -- Care and treatment, Biological products -- Genetic aspects, Pemetrexed, Lung cancer, Non-small cell -- Care and treatment -- Genetic aspects, Chemotherapy, Cancer -- Chemotherapy, Epidermal growth factor -- Genetic aspects, Business, Business, international, Telecommunications industry
Abstract

Merck, known as MSD outside of the United States and Canada, reported that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to sacituzumab tirumotecan (sac-TMT) for [...]

Published
2024

23. Tagrisso recommended for EU approval - LAURA

Subjects
AstraZeneca PLC, Lung cancer, Non-small cell -- Care and treatment -- Genetic aspects, Clinical trials, Epidermal growth factor -- Genetic aspects, Pharmaceutical industry, Business, international, European Union, Tagrisso (Medication)
Abstract

Helsinki: AstraZeneca PLC has issued the following news release: AstraZeneca's Tagrisso (osimertinib) has been recommended for approval in the European Union (EU) for the treatment of adult patients with locally [...]

Published
2024

24. Results from the FURTHER Trial Demonstrate Firmonertinib is a Promising Potential Therapy for Patients with NSCLC with EGFR PACC Mutations

Subjects
Metastasis -- Genetic aspects -- Care and treatment, Lung cancer, Non-small cell -- Care and treatment -- Genetic aspects, Clinical trials, Business, News, opinion and commentary
Abstract

The tyrosine kinase inhibitor firmonertinib showed promising efficacy in patients with non-small cell lung cancer across a broad range of EGFR PACC mutations in the first-line metastatic setting with CNS [...]

Published
2024

25. US FDA grants breakthrough therapy designation to Bayer's BAY 2927088 for NSCLC harbouring HER2 activating mutations

Subjects
Bayer AG, United States. Food and Drug Administration, Care and treatment, Genetic aspects, Gene mutation -- Genetic aspects, Epidermal growth factors -- Genetic aspects, Pharmaceutical industry, Non-small cell lung cancer -- Care and treatment -- Genetic aspects, Gene mutations -- Genetic aspects, Lung cancer, Non-small cell -- Care and treatment -- Genetic aspects, Epidermal growth factor -- Genetic aspects
Abstract

Bayer announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for BAY 2927088 for the treatment of adult patients with unresectable or metastatic non-small cell [...]

Published
2024

26. City of Hope National Medical Center Researcher Has Published New Data on Cancer Gene Therapy [Novel Immunotherapeutics for the Treatment of Non-Small Cell Lung Cancer (NSCLC) Resistant to PD-1/PD-L1 Inhibitors]

Subjects
Care and treatment, Genetic aspects, Reports, Vaccines -- Reports, Genetic research -- Reports -- Genetic aspects, Cancer genetics -- Care and treatment -- Genetic aspects, Medical centers -- Reports, Gene therapy -- Reports, Genes -- Reports -- Genetic aspects, Cancer research -- Reports -- Genetic aspects, Immunotherapy -- Reports, Non-small cell lung cancer -- Care and treatment -- Genetic aspects, Oncology, Experimental -- Reports -- Genetic aspects, Cancer -- Genetic aspects -- Research, Lung cancer, Non-small cell -- Care and treatment -- Genetic aspects
Abstract

2024 NOV 13 (NewsRx) -- By a News Reporter-Staff News Editor at Vaccine Weekly -- Research findings on cancer gene therapy are discussed in a new report. According to news [...]

Published
2024

27. Findings from National University of Singapore Yields New Findings on Cancer Gene Therapy (Customised Design of Antisense Oligonucleotides Targeting Egfr Driver Mutants for Personalised Treatment of Non-small Cell Lung Cancer)

Subjects
National University of Singapore -- Reports, Care and treatment, Genetic aspects, Reports, Health aspects, Cancer treatment -- Health aspects -- Reports, Cancer genetics -- Care and treatment -- Genetic aspects, Gene therapy -- Reports -- Health aspects, Small cell lung cancer -- Genetic aspects -- Care and treatment, Epidermal growth factors -- Health aspects -- Reports -- Genetic aspects, Non-small cell lung cancer -- Care and treatment -- Genetic aspects, Lung cancer, Small cell -- Genetic aspects -- Care and treatment, Cancer -- Care and treatment -- Genetic aspects, Lung cancer, Non-small cell -- Care and treatment -- Genetic aspects, Epidermal growth factor -- Health aspects -- Reports -- Genetic aspects
Abstract

2024 OCT 22 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- Investigators publish new report on Biotechnology - Cancer Gene Therapy. According to news reporting out [...]

Published
2024

28. Research Conducted at Netherlands Cancer Institute Has Updated Our Knowledge about Small Cell Lung Cancer (Osimertinib-induced Dna Resistance Mutations In Cerebrospinal Fluid of Epidermal Growth Factor Receptor-mutated Non-small-cell Lung ...)

Subjects
Care and treatment, Genetic aspects, Cancer genetics -- Care and treatment -- Genetic aspects, Osimertinib, Cancer research -- Genetic aspects, DNA -- Genetic aspects, Small cell lung cancer -- Genetic aspects -- Care and treatment, Epidermal growth factors -- Genetic aspects, Non-small cell lung cancer -- Care and treatment -- Genetic aspects, Oncology, Experimental -- Genetic aspects, Lung cancer, Small cell -- Genetic aspects -- Care and treatment, Cancer -- Genetic aspects -- Research, Lung cancer, Non-small cell -- Care and treatment -- Genetic aspects, Epidermal growth factor -- Genetic aspects
Abstract

2024 SEP 30 (NewsRx) -- By a News Reporter-Staff News Editor at Respiratory Therapeutics Week -- Data detailed on Oncology - Small Cell Lung Cancer have been presented. According to [...]

Published
2024

29. New Findings Reported from George Emil Palade University of Medicine Describe Advances in Non-Small Cell Lung Cancer (Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratio: Side by Side with Molecular Mutations in Patients with Non-Small ...)

Subjects
Care and treatment, Analysis, Genetic aspects, Lymphocytes -- Genetic aspects -- Analysis, Small cell lung cancer -- Genetic aspects -- Care and treatment, Non-small cell lung cancer -- Care and treatment -- Genetic aspects, Lung cancer, Small cell -- Genetic aspects -- Care and treatment, Lung cancer, Non-small cell -- Care and treatment -- Genetic aspects
Abstract

2024 SEP 13 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Data detailed on non-small cell lung cancer have been presented. According to news [...]

Published
2024

30. RYBREVANT(r)V (amivantamab) in combination with chemotherapy is the first therapy approved by the European Commission for the first-line treatment of patients with advanced non-small cell lung cancer with activating EGFR exon 20 insertion mutations

Subjects
Johnson & Johnson, Lung cancer, Small cell -- Genetic aspects -- Care and treatment, Pemetrexed, Chemotherapy, Drug approval, Lung cancer, Non-small cell -- Care and treatment -- Genetic aspects, Cancer -- Chemotherapy, Epidermal growth factor -- Genetic aspects, Pharmaceutical industry, General interest, News, opinion and commentary, European Union. European Commission, Rybrevant (Medication)
Abstract

BEERSE: Janssen Cilag International NV has issued the following news release: Janssen-Cilag International NV, a Johnson & Johnson company, announced today that the European Commission (EC) has approved a Type [...]

Published
2024

31. InxMed Reports Positive Phase Ib|II Results for Ifebemtinib in Combination with Garsorasib in Non-Small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation

Subjects
Lung cancer, Small cell -- Genetic aspects -- Care and treatment, Lung cancer, Non-small cell -- Care and treatment -- Genetic aspects, Clinical trials, General interest, News, opinion and commentary
Abstract

NANJING: InxMed Ltd has issued the following press release: InxMed Co., Ltd, a clinical-stage biotechnology company developing innovative therapies against tumor-treatment resistance and metastasis, today announced results from the Phase [...]

Published
2024

32. Sunvozertinib's Global Pivotal WU-KONG1B Study Meets Primary Endpoint in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Subjects
Oncology, Experimental -- Genetic aspects, Lung cancer, Small cell -- Genetic aspects -- Care and treatment, Cancer -- Care and treatment -- Research, Lung cancer, Non-small cell -- Care and treatment -- Genetic aspects, Business, News, opinion and commentary
Abstract

The global pivotal WU-KONG1B study investigating sunvozertinib achieved its primary objective with a manageable safety profile in relapsed or refractory NSCLC with EGFR exon20ins. An ongoing randomized global Phase III [...]

Published
2024

33. Mirati Therapeutics gets EMA Committeeas positive opinion for Krazati as targeted treatment option for patients with advanced NSCLC with a KRASG12C mutation

Subjects
Krazati (Medication), Care and treatment, Genetic aspects, Non-small cell lung cancer -- Care and treatment -- Genetic aspects, Lung cancer, Non-small cell -- Care and treatment -- Genetic aspects
Abstract

Mirati Therapeutics, Inc., a commercial stage biotechnology company, announced that following a re-examination procedure, the company has received a positive opinion from the European Medicine Agency's (EMA) Committee for Medicinal [...]

Published
2023

34. Mirati Therapeutics gets EMA Committee's positive opinion for Krazati as targeted treatment option for patients with advanced NSCLC with a KRASG12C mutation

Subjects
Krazati (Medication), Care and treatment, Genetic aspects, Non-small cell lung cancer -- Care and treatment -- Genetic aspects, Lung cancer, Non-small cell -- Care and treatment -- Genetic aspects
Abstract

Mirati Therapeutics, Inc., a commercial stage biotechnology company, announced that following a re-examination procedure, the company has received a positive opinion from the European Medicine Agency's (EMA) Committee for Medicinal [...]

Published
2023

35. Data on Kinase Inhibitors Detailed by Researchers at University of South Florida Morsani (The broad spectrum of tyrosine kinase inhibitors. Treatment of a rare R776H mutation with Osimertinib: Case report)

Subjects
Care and treatment, Genetic aspects, Physical fitness, Osimertinib, Practice guidelines (Medicine), Gene mutation -- Genetic aspects, Tyrosine -- Genetic aspects, Non-small cell lung cancer -- Care and treatment -- Genetic aspects, Phenols (Class of compounds), Gene mutations -- Genetic aspects, Phenols, Lung cancer, Non-small cell -- Care and treatment -- Genetic aspects
Abstract

2023 SEP 23 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- New research on kinase inhibitors is the subject of a new report. [...]

Published
2023

36. InxMed Reports Positive Phase Ib/II Results for Ifebemtinib in Combination with Garsorasib in Non-Small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation

Subjects
Lung cancer, Small cell -- Genetic aspects -- Care and treatment, Lung cancer, Non-small cell -- Care and treatment -- Genetic aspects, Clinical trials -- Health aspects, Company earnings/profit, Business, News, opinion and commentary
Abstract

Ifebemtinib in combination with garsorasib in NSCLC showed ORR of 90.3% and DCR of 96.8% Ifebemtinib is a highly selective, orally administered, focal adhesion kinase inhibitor with significant synergies with [...]

Published
2024

37. FDA Grants Breakthrough Therapy Designation to Sunvozertinib for the First-Line Treatment of Patients with advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

Subjects
United States. Food and Drug Administration, Patient compliance, Lung cancer, Small cell -- Genetic aspects -- Care and treatment, Lung cancer, Non-small cell -- Care and treatment -- Genetic aspects, Epidermal growth factor -- Genetic aspects, Business, News, opinion and commentary
Abstract

SHANGHAI, April 7, 2024 /PRNewswire/ -- Dizal (688192.SH) today announced that the U.S. Food and Drug Administration ('FDA') has granted Breakthrough Therapy Designation (BTD) to its sunvozertinib as the first-line [...]

Published
2024

38. BerGenBio Announces Initiation of Phase 2a in First Line Non-Small Lung Cancer Patients with a STK11 mutation

Subjects
Cancer patients -- Care and treatment, Clinical trials, Lung cancer, Non-small cell -- Care and treatment -- Genetic aspects, General interest, News, opinion and commentary
Abstract

BERGEN, Norway: BerGenBio ASA has issued the following news release: BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced [...]

Published
2024

39. BerGenBio ASA: Announces Initiation of Phase 2a in First Line Non-Small Lung Cancer Patients with a STK11 mutation

Subjects
Cancer patients -- Care and treatment, Lung cancer, Non-small cell -- Care and treatment -- Genetic aspects, Business, international
Abstract

Oslo: BerGenBio ASA has issued the following news release: BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today [...]

Published
2024

40. Research Conducted at Sun Yat-sen University Has Updated Our Knowledge about Personalized Medicine (Co-occurring Egfr P.e709x Mutation Mediates Primary Resistance To the Third-generation Egfr-tkis In Egfr P.g719x-mutant Patients With Advanced ...)

Subjects
National Comprehensive Cancer Network, Care and treatment, Genetic aspects, Precision medicine, Osimertinib, Afatinib, Non-small cell lung cancer -- Care and treatment -- Genetic aspects, Lung cancer, Non-small cell -- Care and treatment -- Genetic aspects
Abstract

2024 JUL 19 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Researchers detail new data in Drugs and Therapies - Personalized Medicine. According to [...]

Published
2024

41. Study Results from Tianjin Medical University Cancer Institute and Hospital Broaden Understanding of Non-Small Cell Lung Cancer (Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: a real-world study)

Subjects
Care and treatment, Genetic aspects, Health aspects, Epidermal growth factor receptors -- Health aspects, Gene mutation -- Health aspects, Non-small cell lung cancer -- Care and treatment -- Genetic aspects, Gene mutations -- Health aspects, Lung cancer, Non-small cell -- Care and treatment -- Genetic aspects
Abstract

2023 APR 8 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on non-small cell lung cancer. According to news [...]

Published
2023

42. Data on Carcinosarcomas Reported by Researchers at First People's Hospital (Neoadjuvant osimertinib and chemotherapy for stage IIIA primary pulmonary carcinosarcoma with EGFR 19DEL mutation: A case report)

Subjects
Care and treatment, Genetic aspects, Physical fitness, Osimertinib, Cancer -- Care and treatment -- Genetic aspects, Chemotherapy, Epidermal growth factors -- Genetic aspects, Non-small cell lung cancer -- Care and treatment -- Genetic aspects, Lung cancer, Non-small cell -- Care and treatment -- Genetic aspects, Cancer -- Care and treatment -- Genetic aspects -- Chemotherapy, Epidermal growth factor -- Genetic aspects
Abstract

2023 APR 1 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Data detailed on carcinosarcomas have been presented. According to news originating from [...]

Published
2023

43. Studies Conducted at Nagoya University on Non-Small Cell Lung Cancer Recently Reported (Stiffer-matrix-induced Pgc-1 Alpha Upregulation Enhanced Mitochondrial Biogenesis and Oxidative Stress Resistance In Non-small Cell Lung Cancer)

Subjects
Care and treatment, Genetic aspects, Health aspects, Mitochondrial biogenesis -- Health aspects, Oxidative stress -- Health aspects, Non-small cell lung cancer -- Care and treatment -- Genetic aspects, Genetic regulation -- Health aspects, Lung cancer, Non-small cell -- Care and treatment -- Genetic aspects
Abstract

2023 FEB 18 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on Oncology - Non-Small Cell Lung Cancer have been [...]

Published
2023

44. New Brain Metastasis Study Results Reported from Qinghai University (Rt-based Combination Therapy for Brain Metastasis From Nsclc With Non-egfr Mutation/alk Gene Rearrangement: a Network Meta-analysis)

Subjects
Care and treatment, Genetic aspects, Research, Cancer research, Gene mutation -- Research, Radiotherapy -- Research, Non-small cell lung cancer -- Care and treatment -- Genetic aspects, Cancer metastasis -- Care and treatment -- Genetic aspects, Brain cancer -- Care and treatment -- Genetic aspects, Combined modality therapy -- Research, Oncology, Experimental, Gene mutations -- Research, Metastasis -- Care and treatment -- Genetic aspects, Lung cancer, Non-small cell -- Care and treatment -- Genetic aspects, Cancer -- Research
Abstract

2023 JAN 21 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators discuss new findings in Brain Diseases and Conditions - Brain Metastasis. [...]

Published
2023

45. Bayer Receives U.S. FDA Breakthrough Therapy Designation for BAY 2927088 For Non-Small Cell Lung Cancer Harboring HER2 Activating Mutations

Subjects
United States. Food and Drug Administration, Bayer AG, Gene mutations -- Genetic aspects, Lung cancer, Small cell -- Genetic aspects -- Care and treatment, Lung cancer, Non-small cell -- Care and treatment -- Genetic aspects, Epidermal growth factor -- Genetic aspects, Pharmaceutical industry, General interest, News, opinion and commentary
Abstract

BERLIN: Bayer announces that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation for BAY 2927088 for the treatment of adult patients with unresectable or metastatic non-small cell [...]

Published
2024

46. Bayer Receives U.S. FDA Breakthrough Therapy Designation for BAY 2927088 for Non-Small Cell Lung Cancer Harboring HER2 Activating Mutations

Subjects
United States. Food and Drug Administration, Bayer AG, Gene mutations -- Genetic aspects, Lung cancer, Small cell -- Genetic aspects -- Care and treatment, Lung cancer, Non-small cell -- Care and treatment -- Genetic aspects, Epidermal growth factor -- Genetic aspects, Pharmaceutical industry, News, opinion and commentary
Abstract

BERLIN--(BUSINESS WIRE)--Feb 26, 2024-- Bayer announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for BAY 2927088 for the treatment of adult patients with [...]

Published
2024

47. Bayer receives US FDA Breakthrough Therapy designation for BAY 2927088 for non-small cell lung cancer harbouring HER2 activating mutations

Subjects
United States. Food and Drug Administration, Bayer AG, Gene mutations -- Genetic aspects, Lung cancer, Small cell -- Genetic aspects -- Care and treatment, Lung cancer, Non-small cell -- Care and treatment -- Genetic aspects, Epidermal growth factor -- Genetic aspects, Business, Chemicals, plastics and rubber industries
Abstract

Bayer announced on 26 Feb 2024 that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for BAY 2927088 for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumours have activating HER2 (ERBB2) mutations, and who have received a prior systemic therapy. BAY 2927088 is an oral, reversible tyrosine kinase inhibitor (TKI) that potently inhibits mutant human epidermal growth factor receptors 2 (HER2), including HER2 exon 20 insertions and HER2 point mutations, as well as epidermal growth factor receptors (EGFR), with high selectivity for mutant vs wild-type EGFR. The Breakthrough Therapy designation is supported by preliminary clinical evidence from the Phase I, open-label, multicentre first-in-human study (NCT05099172) evaluating the safety, pharmacokinetics and preliminary efficacy of BAY 2927088 in adult patients with advanced NSCLC harbouring HER2 or EGFR. Original source: Bayer, website:http://www.bayer.com/, Copyright Bayer AG 2024., regulations and rulings; research and development; anticancer drugs; enzyme inhibitors; [...]

Published
2024

48. European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

Subjects
Drug approval, Lung cancer, Non-small cell -- Care and treatment -- Genetic aspects, Business, News, opinion and commentary, Krazati (Medication)
Abstract

SAN DIEGO and ZUG, Switzerland, Jan. 10, 2024 /PRNewswire/ -- https://c212.net/c/link/?t=0&l=en&o=4064737-1&h=1009758736&u=https%3A%2F%2Fwww.mirati.com%2F&a=Mirati+Therapeutics%2C+Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, today announced that the European Commission (EC) granted conditional marketing authorization for [...]

Published
2024

49. Researchers from Jiangxi Provincial People's Hospital Discuss Research in Non-Small Cell Lung Cancer (Current status and breakthroughs in treating advanced non-small cell lung cancer with EGFR exon 20 insertion mutations)

Subjects
Care and treatment, Genetic aspects, Reports, Precision medicine -- Reports, Cancer research -- Reports -- Genetic aspects, Biochemistry -- Genetic aspects -- Reports, Small cell lung cancer -- Genetic aspects -- Care and treatment, Immunotherapy -- Reports, Non-small cell lung cancer -- Care and treatment -- Genetic aspects, Oncology, Experimental -- Reports -- Genetic aspects, Lung cancer, Small cell -- Genetic aspects -- Care and treatment, Lung cancer, Non-small cell -- Care and treatment -- Genetic aspects, Cancer -- Research
Abstract

2024 MAY 22 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Research findings on non-small cell lung cancer are discussed in a new report. According to [...]

Published
2024

50. Findings from Novartis Pharmaceuticals Corporation Broaden Understanding of Non-Small Cell Lung Cancer (Effectiveness of Standard Treatments In Non-small-cell Lung Cancer With Metexon14 Skipping Mutation: a Real-world Study)

Subjects
Novartis Pharmaceuticals Corp. -- Reports, Care and treatment, Standards, Genetic aspects, Reports, Cancer research -- Reports -- Genetic aspects, Small cell lung cancer -- Genetic aspects -- Care and treatment, Immunotherapy -- Reports, Pharmaceutical industry -- Standards, Non-small cell lung cancer -- Care and treatment -- Genetic aspects, Oncology, Experimental -- Reports -- Genetic aspects, Lung cancer, Small cell -- Genetic aspects -- Care and treatment, Lung cancer, Non-small cell -- Care and treatment -- Genetic aspects, Cancer -- Research
Abstract

2024 MAY 15 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- New research on Oncology - Non-Small Cell Lung Cancer is the subject of a report. [...]

Published
2024

Catalog

Books, media, physical & digital resources
See catalog results